Articles by Vanessa Ira
The findings are notable for a patient population that has limited treatment options.
Cell-free DNA (cfDNA) methylation may be used to predict treatment response in patients with muscle-invasive bladder cancer.
The TheraP ANZUP 1603 trial showed both options were suitable for men with mCRPC.
The treatment was also compared to an active comparator of non-steroidal anti-androgen.
Researchers hypothesized that switch maintenance therapy with the TKI would improve outcomes for the metastatic disease.
The data were from a randomized phase-2 study assessing new treatment combinations in patients with advanced clear cell RCC.
The findings could lead to improved outcomes in men with PSMA PET-positive mCRPC.
Researchers found it had clinical efficacy regardless of patients' prior treatment or standard of care chosen.
The results mean that progression-free survival endpoints could be used to expediate phase-3 clinical trials.
The rate of relapses occurring 2 or 5 years after disease-free survival is low among testicular cancer patients, study finds.
The association between health-related quality of life and clinical outcomes was identified in the CheckMate 214 study.
There were previously no data comparing second-generation ARIs with first-generation ARIs.
Focal ablative salvage therapy may confer good oncological control for patients with recurrent cancer.
The mental health data comes from one of the largest randomized-controlled trials to date.
Estimation of life expectancy is critical for evaluating the benefit of PSA screening for prostate cancer.
Researchers evaluated a hypothetical pragmatic trial of adjuvant radiotherapy in patients with pN1 prostate cancer.
Minorities experience disparities in shared decision-making when it comes to discussions on the advantages of PSA testing.
The findings suggest potential opportunities for more targeted therapy in aggressive prostate cancer.
Research findings show the benefits of vegetarian, vegan, and other plant-based diets for patients with prostate cancer.
Uptake of active surveillance remains suboptimal for patients with low-risk prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.